Activist Investors Bid $2.25 Per Share to Take Over SEER
Activist investors offer to buy Seer for $2.25/share cash + CVR, criticize CEO, and push board to respond by Apr 22.
/ 193 items
#XY Event-Driven Stocks↓
Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.
Allogene’s Off-the-Shelf CAR-T Wipes Out Hidden Cancer Cells in 58% of High-Risk Lymphoma Patients – Early Trial Success
Allogene’s CAR-T cema-cel showed strong early results in lymphoma, removing hidden cancer better than watchful waiting with good safety.
Spyre’s SPY001 Delivers Strong Early Results in Ulcerative Colitis Trial – Shares Jump
Spyre drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.
IDEAYA Shares Surge After Positive Phase 2/3 Results in Hard-to-Treat Eye Cancer
New drug combo shows strong results in rare eye cancer, slowing disease and shrinking tumors; approval filing planned for 2026.
FDA Rejects Replimune’s Skin Cancer Drug for the Second Time
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.